Circulation 56 , 605612 (1977)
Safety risks primarily arise from unverified sources and non-compliant injectable routes
For thyroid patients, these approaches should be tailored to accommodate any fatigue, joint problems, or other symptoms that may limit exercise capacity
Who Is at Higher Risk for Mood Changes on Tirzepatide and GLP-1 Therapy People with a history of major depressive disorder, bipolar disorder, prior suicidal ideation, or unstable psychiatric conditions face a higher risk for psychiatric adverse events on any weight loss drug
Longterm risks are rare but include pancreatitis, gallbladder disease and, in animal studies, thyroid tumours
What's the appropriate dose, frequency, duration